Jefferies

PRINCETON, N.J. – November 10, 2026 -- CytoSorbents Corporation (NASDAQ: CTSO) will send CEO Dr. Phillip Chan and CFO Peter Mariani to the Jefferies Global Healthcare Conference in London on November 16-18, 2026, for one-on-one investor meetings.

Investors can book CytoSorbents management meetings through the Jefferies conference website

Meetings can be scheduled through the conference website, or through the company's investor relations team for sessions outside the event. The conference is in its 17th year and is Jefferies' flagship European healthcare investment gathering. It draws C-suite executives, public, private equity and venture capital investors, and strategists across biotech, pharmaceuticals, medical technology, healthcare services, digital health and healthcare IT.

Cambridge, Mass. – November 06, 2026 -- CREATE Medicines, Inc. says it has treated more than 80 patients with in vivo CAR therapy, which it describes as the largest clinical dataset in the field. The company is now taking its four clinical-stage programs to investors and prospective partners at the Jefferies Global Healthcare Conference in London.

CREATE schedules one-on-one meetings at Jefferies London on Nov. 16-19, 2026

Management will hold one-on-one meetings at the Waldorf Hilton and ME London during the conference, which runs from Nov. 16 to 19, 2026. CEO and Co-Founder Daniel Getts, PhD, and Chief Medical Officer Matthew Maurer, MD, will represent the clinical-stage biotech.

Investors must request meetings through their Jefferies representative. Prospective partners can contact the company's business development team directly.

PLYMOUTH MEETING, Pa. – November 05, 2026 -- INOVIO Pharmaceuticals (Nasdaq: INO) plans to raise capital through an underwritten public offering of its common stock, with all shares sold by the company itself.

Underwriters hold a 30-day option on up to 15% additional shares

INOVIO intends to grant the underwriters a 30-day option to buy additional shares, capped at 15% of the shares sold in the base offering and priced on the same terms. The company has not disclosed the number of shares or the pricing. It said there is no assurance the offering will be completed, or on what size or terms, and that it remains subject to market conditions.

Jefferies and Piper Sandler are acting as joint book-running managers.

TORONTO – November 03, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL; TSX: CRDL) has entered into an at-the-market program that lets it sell up to US$75 million of common shares through Jefferies LLC to fund late-stage cardiac drug development.

Cardiol restricts ATM share sales to U.S. trading venues

Shares will be sold in ordinary brokers' transactions on the Nasdaq Capital Market or other U.S. trading markets at prevailing market prices. No shares will be sold through the Toronto Stock Exchange or elsewhere in Canada.

Sales will proceed under a prospectus supplement dated November 3, 2026. The supplement attaches to Cardiol's Canadian and U.S. base shelf prospectuses, both dated September 15, 2026. The U.S. base prospectus forms part of a Form F-10 registration statement that became effective on September 16, 2026.